Rocatinlimab for atopic dermatitis: Rebalancing immunity by targeting pathogenic T cells
-
-
REFERENCES
[1] Guttman-Yassky E., Renert-Yuval Y. and Brunner P.M. (2025). Atopic dermatitis. Lancet 405:583−596. DOI:10.1016/S0140-6736(24)02519-4 [2] Croft M., Esfandiari E., Chong C., et al. (2024). OX40 in the pathogenesis of atopic dermatitis—a new therapeutic target. Am. J. Clin. Dermatol. 25:447−461. DOI:10.1007/s40257-023-00838-9 [3] Iriki H., Takahashi H. and Amagai M. (2023). Diverse role of OX40 on T cells as a therapeutic target for skin diseases. J. Invest. Dermatol. 143:545−553. DOI:10.1016/j.jid.2022.11.009 [4] Simpson E.L., Bieber T., Guttman-Yassky E., et al. (2016). Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N. Engl. J. Med. 375:2335−2348. DOI:10.1056/NEJMoa1610020 [5] Guttman-Yassky E., Kabashima K., Worm M., et al. (2025). Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: Two global, double-blind, placebo-controlled, randomised phase 3 clinical trials. Lancet 407:53−66. DOI:10.1016/S0140-6736(25)01865-3 -
ABOUT THIS ARTICLE
Cite this article:
Cheng A., Li J., Wang Z., et al. (2026). Rocatinlimab for atopic dermatitis: Rebalancing immunity by targeting pathogenic T cells. The Innovation Medicine 4:100254. https://doi.org/10.59717/j.xinn-med.2026.100254
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
Cheng A., Li J., Wang Z., et al. (2026). Rocatinlimab for atopic dermatitis: Rebalancing immunity by targeting pathogenic T cells. The Innovation Medicine 4:100254. https://doi.org/10.59717/j.xinn-med.2026.100254
Format
Content
DownLoad:
-
Figure 1.
Mechanistic comparison of therapeutic paradigms in atopic dermatitis: Downstream cytokine blockade versus upstream T-cell rebalancing
